“The FDA is rarely that clear, so this is refreshing.” — Paul Knoepfler, PhD, of the University of California Davis, on the FDA getting tougher on birth tissue injection companies, following a recent warning letter to one company in question.
“Everyone is at risk.” — Ziyad Al-Aly, MD, of Washington University in St. Louis, on avoiding infection and reinfection in the first place to prevent long COVID.
“The vast majority of restaurants … handle food that is not prepared properly, and could easily poison us, and they do it every day, millions of times a day.” — Jacob Sherkow, JD, of the Illinois College of Medicine, in an analogy referring to the risks that compounding pharmacies run in producing off-brand semaglutide (Wegovy).
“This strikes a chord for me. I’ve seen firsthand, every single day, how difficult it can be for kids to access care.” — Lisa Gwynn, MD, president of the Florida chapter of the American Academy of Pediatrics, on how advocating for equitable COVID vaccine access for young kids in her state cost her a spot on a state board.
“Until we have a handle on all of the endotypes, narrowing the scope of a definition would be an unmitigated disaster.” — David Putrino, PhD, of Mount Sinai Health System in New York, advising the medical community to pump the breaks when settling on a definition for long COVID.
“This level of mortality is significantly higher than expected.” — David Boulware, MD, MPH, of the University of Minnesota in Minneapolis, on the high mortality rate in a small control group of hospitalized COVID-19 patients in a recent trial of the investigational treatment sabizabulin.
Please enable JavaScript to view the